Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.95USD
10:54am EDT
Change (% chg)

$0.21 (+0.49%)
Prev Close
$42.74
Open
$42.88
Day's High
$43.03
Day's Low
$42.55
Volume
620,638
Avg. Vol
6,601,491
52-wk High
$46.46
52-wk Low
$37.12

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat
Tuesday, 2 Jul 2019 08:00am EDT 

July 2 (Reuters) - Calithera Biosciences Inc ::CALITHERA BIOSCIENCES INITIATES PHASE 1/2 TRIAL OF TELAGLENASTAT IN COMBINATION WITH PFIZER’S CDK4/6 INHIBITOR PALBOCICLIB.CALITHERA BIOSCIENCES - ANNOUNCED TREATMENT OF FIRST PATIENT IN PHASE 1/2 TRIAL OF GLUTAMINASE INHIBITOR TELAGLENASTAT WITH PFIZER'S IBRANCE.CALITHERA BIOSCIENCES INC - AS PART OF AGREEMENT, PFIZER IS PROVIDING PALBOCICLIB AND TALAZOPARIB, AS WELL AS FINANCIAL SUPPORT.  Full Article

Pfizer Announces Positive Top-Line Results From Phase 4 Study Of Crisaborole Ointment
Monday, 1 Jul 2019 08:00am EDT 

July 1 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 4 STUDY OF CRISABOROLE OINTMENT, 2%, IN CHILDREN AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS.PFIZER INC - SAFETY PROFILE CONSISTENT WITH PREVIOUS CLINICAL TRIAL EXPERIENCE.PFIZER INC - DATA SHOW CRISABOROLE OINTMENT, 2%, A STEROID-FREE TOPICAL TREATMENT, WAS WELL-TOLERATED OVER 4-WEEK TREATMENT PERIOD.PFIZER INC - SAFETY PROFILE CONSISTENT WITH PREVIOUS CLINICAL TRIAL EXPERIENCE.PFIZER INC - STUDY DATA SHOW CRISABOROLE OINTMENT, 2%, A STEROID-FREE TOPICAL TREATMENT, WAS WELL-TOLERATED OVER 4-WEEK TREATMENT PERIOD.  Full Article

Pfizer Announces Results From Phase 3 Trial Of Revatio (Sildenafil Citrate) In Newborns With Persistent Pulmonary Hypertension
Friday, 28 Jun 2019 04:05pm EDT 

June 28 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF REVATIO (SILDENAFIL CITRATE) IN NEWBORNS WITH PERSISTENT PULMONARY HYPERTENSION.PFIZER INC - PHASE 3 STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT.PFIZER - TREATMENT WITH IV SILDENAFIL WHEN ADDED TO INO DID NOT RESULT IN STATISTICALLY SIGNIFICANT REDUCTION IN TREATMENT FAILURE RATE OR TIME ON INO.  Full Article

Pfizer Sets Quarterly Cash Dividend Of $0.36 Per Share
Thursday, 27 Jun 2019 04:15pm EDT 

June 27 (Reuters) - Pfizer Inc ::SETS QUARTERLY CASH DIVIDEND OF $0.36PER SHARE.  Full Article

Biomarin Earns Milestone Payments From Pfizer
Friday, 21 Jun 2019 11:30am EDT 

June 21 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN EARNS MILESTONE PAYMENTS FROM PFIZER FOR TALZENNA® (TALAZOPARIB) FOR METASTATIC BREAST CANCER PATIENTS WITH AN INHERITED BRCA MUTATION.BIOMARIN PHARMACEUTICAL INC - EUROPEAN COMMISSION APPROVAL TRIGGERS $15 MILLION PAYMENT.BIOMARIN PHARMACEUTICAL INC - BIOMARIN ENTITLED TO EARN MID-SINGLE DIGIT ROYALTIES ON FUTURE SALES.BIOMARIN PHARMACEUTICAL INC - COMPANY EARNED A $15 MILLION MILESTONE PAYMENT FROM PFIZER.BIOMARIN PHARMACEUTICAL INC - $15 MILLION MILESTONE PAYMENT WAS TRIGGERED BY EUROPEAN COMMISSION APPROVAL OF TALZENNA.  Full Article

Pfizer To Acquire Array Biopharma For $48/share In Cash
Monday, 17 Jun 2019 06:45am EDT 

June 17 (Reuters) - Array Biopharma Inc ::PFIZER TO ACQUIRE ARRAY BIOPHARMA.ARRAY BIOPHARMA INC - DEAL FOR $48 PER SHARE IN CASH.ARRAY BIOPHARMA INC - DEAL FOR TOTAL ENTERPRISE VALUE OF APPROXIMATELY $11.4 BILLION.ARRAY BIOPHARMA INC - TRANSACTION VALUED AT $48 PER ARRAY SHARE IN CASH, FOR A TOTAL ENTERPRISE VALUE OF APPROXIMATELY $11.4 BILLION.ARRAY BIOPHARMA INC - PFIZER EXPECTS TO FINANCE MAJORITY OF DEAL WITH DEBT AND BALANCE WITH EXISTING CASH.ARRAY BIOPHARMA INC - BOARDS OF DIRECTORS OF BOTH COMPANIES HAVE APPROVED MERGER.ARRAY BIOPHARMA INC - TRANSACTION IS EXPECTED TO BE DILUTIVE TO PFIZER'S ADJUSTED DILUTED EPS BY $0.04 -$0.05 IN 2019.ARRAY BIOPHARMA INC - UPON CLOSE OF TRANSACTION, ARRAY'S EMPLOYEES WILL JOIN PFIZER.ARRAY BIOPHARMA INC - DEAL EXPECTED TO BE DILUTIVE TO PFIZER'S ADJUSTED DILUTED EPS BY $0.04 -$0.05 IN 2020, NEUTRAL IN 2021.ARRAY BIOPHARMA INC - PFIZER EXPECTS TO COMPLETE ACQUISITION IN SECOND HALF OF 2019.ARRAY BIOPHARMA INC - TRANSACTION IS EXPECTED TO BE ACCRETIVE TO PFIZER BEGINNING IN 2022.ARRAY BIOPHARMA INC - PLANS TO MAINTAIN PRODUCTIVE RESEARCH UNIT IN BOULDER TO COMPLEMENT PFIZER'S RESEARCH HUBS.ARRAY BIOPHARMA - AGREEMENT CONTEMPLATES THAT PFIZER WILL ACQUIRE ANY SHARES OF ARRAY THAT ARE NOT TENDERED INTO OFFER THROUGH A SECOND-STEP MERGER.ARRAY BIOPHARMA INC - PFIZER WILL PROVIDE ANY UPDATES TO ITS CURRENT 2019 GUIDANCE IN CONJUNCTION WITH ITS Q3 2019 EARNINGS RELEASE.  Full Article

Pfizer Announces Results From Xeljanz XR Oral Shift Study, The First Phase 3B/4 Study To Evaluate Methotrexate Withdrawal With A Jak Inhibitor
Wednesday, 12 Jun 2019 08:00am EDT 

June 12 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES RESULTS FROM XELJANZ® XR (TOFACITINIB) ORAL SHIFT STUDY, THE FIRST PHASE 3B/4 STUDY TO EVALUATE METHOTREXATE WITHDRAWAL WITH A JAK INHIBITOR.PFIZER INC - STUDY DEMONSTRATED NON-INFERIORITY OF MTX WITHDRAWAL WITH XELJANZ XR 11 MG QD VERSUS XELJANZ XR 11 MG QD PLUS MTX.PFIZER INC - SAFETY FINDINGS IN ORAL SHIFT INCLUDE MOST FREQUENTLY REPORTED ADVERSE EVENTS (AES) FOR EACH STUDY GROUP.PFIZER INC - IN DOUBLE-BLIND TREATMENT PERIOD, THERE WERE TWO DEATHS REPORTED IN XELJANZ XR PLUS MTX TREATMENT GROUP..  Full Article

Novitium Pharma Launches Generic Revatio For Oral Suspension, 10mg/mL
Tuesday, 4 Jun 2019 12:00pm EDT 

June 4 (Reuters) - Novitium Pharma LLC::NOVITIUM PHARMA - LAUNCHES GENERIC REVATIO FOR ORAL SUSPENSION, 10MG/ML.NOVITIUM PHARMA - GOT FDA CLEARANCE FOR SILDENAFIL FOR ORAL SUSPENSION, 10MG/ML; THE PRODUCT IS THE GENERIC OF PFIZER'S REVATIO FOR ORAL SUSPENSION.  Full Article

Bioxcel Therapeutics Announces FDA Clearance Of IND Application
Monday, 3 Jun 2019 08:00am EDT 

June 3 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR TRIPLE COMBINATION IN PANCREATIC CANCER AND CTA ACCEPTANCE FOR DOUBLE COMBINATION IN AGGRESSIVE FORM OF PROSTATE CANCER (TNEPC) FOR LEAD IMMUNO-ONCOLOGY PROGRAM, BXCL701.BIOXCEL THERAPEUTICS INC - MHRA ACCEPTS CLINICAL APPLICATION FOR DOUBLE COMBINATION TRIAL OF BXCL701 AND KEYTRUDA IN TNEPC PATIENTS.BIOXCEL - COLLABORATING WITH NEKTAR THERAPEUTICS, MERCK KGAA, PFIZER TO CONDUCT TRIAL TO EVALUATE TRIPLE COMBINATION OF BXCL701, BEMPEGALDESLEUKIN & AVELUMAB.  Full Article

Siga Announces TPOXX Promotion Agreement With Meridian Medical Technologies For International Markets
Monday, 3 Jun 2019 07:30am EDT 

June 3 (Reuters) - SIGA Technologies Inc ::SIGA ANNOUNCES TPOXX® PROMOTION AGREEMENT WITH MERIDIAN MEDICAL TECHNOLOGIES, INC. (A PFIZER COMPANY) FOR INTERNATIONAL MARKETS.SIGA TECHNOLOGIES INC - MERIDIAN WILL PROMOTE SALE OF ORAL TPOXX FOR TREATMENT OF SMALLPOX IN ALL MARKETS, EXCEPT FOR UNITED STATES AND SOUTH KOREA.SIGA TECHNOLOGIES INC - SIGA WILL CONTINUE TO BE OWNER OF ALL RIGHTS IN U.S. MARKET.SIGA TECHNOLOGIES INC - AGREEMENT DOES NOT INCLUDE ANY CASH PAYMENTS AT SIGNING.SIGA TECHNOLOGIES INC - MERIDIAN WILL BE COMPENSATED UNDER PROMOTION AGREEMENT THROUGH A FEE BASED ON PERCENTAGE OF NET SALES OF ORAL TPOXX.  Full Article

Photo

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.